Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...